We are now seeing more and more generics for “extended-release” drugs, i.e., diltiazem XT, metformin ER, and others. Can we rely on these to be pharmacokinetically equivalent to the original ...

COLUMBUS, Ohio – Generic drugs manufactured in India are linked to significantly more “severe adverse events” for patients who use them than equivalent drugs produced in the United States, a new study ...

Generic drugs have saved billions of dollars and benefited countless lives by making existing medicines more affordable. But a new study finds these drug copies may not all be created equal. Despite ...

The global generic drugs market revenue was around US$ 416.5 billion in 2023 and is estimated to reach US$ 839.5 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.1% during the ...

Global & regional market size forecasts through 2035. Competitive benchmarking and SWOT analysis of top providers. Segmentation insights. Regulatory and sustainability landscape ...

Prescription drug prices in the United States remain a major financial burden for millions of Americans. As healthcare costs rise and insurance coverage becomes increasingly complex, patients are ...

The United States is amid a dangerous drug shortage that endangers patients, undermines our health care system and exposes a deep vulnerability to national security. America’s overwhelming reliance on ...

Ropinirole belongs to a class of drugs known as a non-ergoline dopamine agonist used to treat symptoms of Parkinson's disease ...

The Food and Drug Administration granted tentative approval to AuroBindo Pharma for dolutegravir, a drug intended to treat patients with HIV, reported Business Standard. Dolutegravir is the generic ...

Attorney General Roy Cooper announced Friday that a major pharmaceutical manufacturer has agreed to stop blocking consumers' access to generic drugs and to pay refunds to consumers. North Carolina ...

Big Pharma is exploiting loopholes that keep generic drugs off the market, a move that drives up costs for consumers, allowing the companies to maximize their profits, two Capitol Hill Democrat argued ...